Hawkins R A, White G, Bundred N J, Dixon J M, Miller W R, Stewart H J, Forrest A P
University Department of Clinical Surgery, Royal Infirmary, Edinburgh, UK.
Br J Surg. 1987 Nov;74(11):1009-13. doi: 10.1002/bjs.1800741118.
The prognostic significance of the tumour activities of 2 steroid receptors, those for oestrogen (ER) and for progestogen (PgR), has been studied in 372 patients with breast cancer, in whom follow-up was available for 2-6 years (median 41 months). Of 252 patients with operable disease, 75.8 per cent had ER-positive tumours and 46.4 per cent had PgR-positive tumours, though a small additional fraction (6.3 per cent) had an equivocal PgR assay result. For the 236 patients with unequivocal receptor status, the relationships between disease-free interval or overall survival and receptor activity and other factors were evaluated by univariate and multivariate analyses. The latter revealed that only tumour size, node status, menstrual status and ER status related significantly to both disease-free interval and survival, though adjuvant therapy also related to disease-free interval, and tumour grade related to survival. It is concluded that measurements of PgR activity do not add to the prognostic significance of ER status.
对372例乳腺癌患者研究了两种甾体激素受体（雌激素受体和孕激素受体）的肿瘤活性的预后意义，这些患者的随访时间为2至6年（中位数41个月）。在252例可手术治疗的患者中，75.8%的患者肿瘤雌激素受体阳性，46.4%的患者肿瘤孕激素受体阳性，不过另有一小部分患者（6.3%）的孕激素受体检测结果不明确。对于236例受体状态明确的患者，通过单因素和多因素分析评估了无病生存期或总生存期与受体活性及其他因素之间的关系。多因素分析显示，仅肿瘤大小、淋巴结状态、月经状态和雌激素受体状态与无病生存期和生存率均显著相关，不过辅助治疗也与无病生存期相关，肿瘤分级与生存率相关。得出的结论是，孕激素受体活性检测并未增加雌激素受体状态的预后意义。
